The US Food and Drug Administration (FDA) has approved Synjardy (empagliflozin and metformin hydrochloride) tablets, from Boehringer Ingelheim Pharmaceuticals, Inc (BI). and Eli Lilly and Company for treating adults with Type 2 diabetes. Synjardy is the third product containing empagliflozin to be approved by the FDA, following Jardiance (empagliflozin) and Glyxambi (empagliflozin/linagliptin). The drug was also recently approved by the European Medicines Agency in May 2015.

Synjardy is a combination of empagliflozin and metformin, two medicines with complementary mechanisms of action, to help control blood glucose in people with Type 2 diabetest. Empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor, removes excess glucose through the urine by blocking glucose re-absorption in the kidney. Metformin lowers glucose production by the liver and its absorption in the intestine.

Synjardy is the fifth FDA-approved medicine from the BI-Lilly diabetes alliance pipeline in the last four years.

Source: Boehringer Ingelheim